# Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)

> **NCT01292135** · PHASE1 · COMPLETED · sponsor: **Pharmacyclics LLC.** · enrollment: 33 (actual)

## Conditions studied

- B-cell Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** PCI-32765

## Key facts

- **NCT ID:** NCT01292135
- **Lead sponsor:** Pharmacyclics LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2012-11
- **Final completion:** 2013-05
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2014-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01292135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01292135, "Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01292135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*